Clinical applications of hallucinogens: a review

Garcia-Romeu, Albert, Kersgaard, Brennan, Addy, Peter H.·2016·Experimental and Clinical Psychopharmacology
DOI 10.1037/pha0000084

Cites (531)

Items 401–531 of 531

  1. Differential Effects of Ecstasy on Short-Term and Working Memory: A Meta-Analysis
    Claire E. Nulsen, Allison M. Fox, Geoffrey R. Hammond · 2010 · Neuropsychology Review
  2. Evolution of Concept, But Not Action, in Addiction Treatment
    Amelia M. Arria, A. Thomas McLellan · 2012 · Substance Use & Misuse
  3. Ibogaine neurotoxicity: a re-evaluation
    Helen H. Molinari, I.M. Maisonneuve, S.D. Glick · 1996 · Brain Research
  4. Chronic Psychosis Associated With Long-Term Psychotomimetic Drug Abuse
    George S. Glass · 1970 · Archives of General Psychiatry
  5. Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys
    Kevin B. Freeman, Jennifer E. Naylor, Thomas Edward Prisinzano, William L. Woolverton · 2014 · Psychopharmacology
  6. Quantification of the plant‐derived hallucinogen Salvinorin A in conventional and non‐conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking
    Simona Pichini, Sergio Abanades, Magı́ Farré, Manuela Pellegrini, Emilia Marchei, Roberta Pacifici, Rafael de la Torre, Piergiorgio Zuccaro · 2005 · Rapid Communications in Mass Spectrometry
  7. Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception.
    Wallach, J.V. · 2009 · Medical Hypotheses
  8. 18-MC reduces methamphetamine and nicotine self-administration in rats
    S.D. Glick, I.M. Maisonneuve, Heather A Dickinson · 2000 · Neuroreport
  9. The in vitro identification of dimethyltryptamine (DMT) in mammalian brain and its characterization as a possible endogenous neuroregulatory agent
    Christian, Samuel T., Harrison, Robert, Quayle, Elizabeth, Pagel, John, Monti, John · 1977 · Biochemical Medicine
  10. Bringing Ayahuasca to the Clinical Research Laboratory
    Jordi Riba A, Manel J. Barbanoj · 2005 · Journal of Psychoactive Drugs
  11. Sex Differences in Ibogaine Antagonism of Morphine-induced Locomotor Activity and in Ibogaine Brain Levels and Metabolism
    Sandra M. Pearl, Lindsay B. Hough, D.L Boyd, S.D. Glick · 1997 · Pharmacology Biochemistry and Behavior
  12. The Therapeutic Use of MDMA
    Greer, George R., Tolbert, Requa · 1990 · Topics in the Neurosciences
  13. Effects of self-generated sad mood on regional cerebral activity: A PET study in normal subjects
    Michael C. Gemar, Shitij Kapur, Zindel V. Segal, Gregory M. Brown, Sylvain Houle · 1996 · Depression
  14. The inhibitory effect of norharman on morphine withdrawal syndrome in rats: Comparison with ibogaine
    Susanne L.T. Cappendijk, Durk Fekkes, Michailo R. Dzoljic · 1994 · Behavioural Brain Research
  15. Chromosomal Damage in LSD Users
    José Egozcue · 1968 · JAMA
  16. Dextromethorphan as a potential rapid-acting antidepressant
    Edward C. Lauterbach · 2011 · Medical Hypotheses
  17. Interaction of ibogaine and d-amphetamine: in vivo microdialysis and motor behavior in rats
    I.M. Maisonneuve, Richard W. Keller, S.D. Glick · 1992 · Brain Research
  18. A REVIEW OF THE NEUROPHYSIOLOGICAL EFFECTS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND OTHER PSYCHOTOMIMETIC AGENTS
    Edward V. Evarts · 1957 · Annals of the New York Academy of Sciences
  19. Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies
    Stephen Ross · 2012 · Psychiatric Clinics of North America
  20. Experienced Drug Users Assess the Relative Harms and Benefits of Drugs: A Web-Based Survey
    Robin Lester Carhart-Harris, David Nutt · 2013 · Journal of Psychoactive Drugs
  21. 18‐MC acts in the medial habenula and interpeduncular nucleus to attenuate dopamine sensitization to morphine in the nucleus accumbens
    Olga D. Taraschenko, Joseph M Shulan, Isabelle M. Maisonneuve, Stanley D. Glick · 2007 · Synapse
  22. The effect of Salvia divinorum and Mitragyna speciosa extracts, fraction and major constituents on place aversion and place preference in rats
    Kenneth J. Sufka, Melissa J. Loria, Kevin Lewellyn, Jordan Kordian Zjawiony, Zulfıqar Ali, Naohito Abe, Ikhlas Ahmed Khan · 2013 · Journal of Ethnopharmacology
  23. Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis
    Jörg Daumann, Karsten Heekeren, Anna Neukirch, Christiane M. Thiel, Walter Möller‐Hartmann, Euphrosyne Gouzoulis‐Mayfrank · 2008 · Psychopharmacology
  24. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan
    Edward C. Lauterbach · 2012 · Medical Hypotheses
  25. ‘Ecstasy’ as a social drug: MDMA preferentially affects responses to emotional stimuli with social content
    Margaret C. Wardle, Matthew G. Kirkpatrick, Harriet de Wit · 2014 · Social Cognitive and Affective Neuroscience
  26. Neuropathological evaluation by combined immunohistochemistry and degeneration-specific methods: application to methylenedioxymethamphetamine.
    Andrew C. Scallet, George W. Lipe, Ali Sf, R.Robert Holson, Frith Ch, William Slikker · 1988 · PubMed
  27. Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice
    Nguyen, Linda, Matsumoto, Rae R. · 2015 · Behavioural Brain Research
  28. Psychotropic Drugs as Negative Reinforcers
    Friedrich Hoffmeister, Wolfgang Wuttke · 1975 · Pharmacological Reviews
  29. Computer-assisted modeling of multiple dextromethorphan and sigma binding sites in guinea pig brain
    Guang-Zhao Zhou, José M. Musacchio · 1991 · European Journal of Pharmacology Molecular Pharmacology
  30. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis
    Karsten Heekeren, Anna Neukirch, Jörg Daumann, M. Stoll, M. Obradovic, K.‐A. Kovar, Mark A. Geyer, Euphrosyne Gouzoulis‐Mayfrank · 2007 · Journal of Psychopharmacology
  31. A reconsideration and response to Parrott AC (2013) “Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research”
    Rick Doblin, George R. Greer, Julie A. Holland, Lisa Jerome, Michael C. Mithoefer, Ben Sessa · 2014 · Human Psychopharmacology Clinical and Experimental
  32. The Combination of Psychedelic and Aversive Approaches in Alcoholism Treatment
    Evgeny M. Krupitsky, A. Ya Grineko, Тимур Ниязбекович Беркалиев, A. I. Paley, U. N. Tetrov, K. A. Mushkov, Yu S. Borodikin · 1992 · Alcoholism Treatment Quarterly
  33. Long-QT Syndrome Induced by the Antiaddiction Drug Ibogaine
    Dianne W. M. Hoelen, Wilko Spiering, Gerlof Dirk Valk · 2009 · New England Journal of Medicine
  34. Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-d-aspartate receptors
    Mirna Bainy Leal, Kátia Michelin, Diogo Onofre Souza, Elaine Elisabetsky · 2003 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  35. Structure-Activity Relationships of MDMA-Like Substances
    David E. Nichols, Robert A. Oberlender · 1989 · PsycEXTRA Dataset
  36. Psychopathology and Psychophysiology of Minimal LSD-25 Dosage
    THEODORE H. GREINER · 1958 · A M A Archives of Neurology & Psychiatry
  37. (±)‐18‐Methoxycoronaridine: A NovelIbogaAlkaloid Congener Having Potential Anti‐Addictive Efficacy
    Stanley D. Glick, Isabelle M. Maisonneuve, Lindsay B. Hough, Martin E. Kuehne, Upul K. Bandarage · 1999 · CNS Drug Reviews
  38. Effects of ibogaine on naloxone‐precipitated withdrawal in morphine‐dependent mice
    Bernard Francès, R. Gout, J. Cros, Jean‐Marie Zajac · 1992 · Fundamental and Clinical Pharmacology
  39. 18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats
    S.D. Glick, I.M. Maisonneuve, Kathleen E. Visker, K. A. Fritz, Upul K. Bandarage, Martin E. Kuehne · 1998 · Psychopharmacology
  40. Salvia Divinorum Use among a College Student Sample
    David N. Khey, Bryan Lee Miller, O. Hayden Griffin · 2008 · Journal of Drug Education
  41. Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats
    D. Wei, I.M. Maisonneuve, Martin E. Kuehne, S.D. Glick · 1998 · Brain Research
  42. Blood Flow and Cerebral Laterality in the Mescaline Model of Psychosis
    Hermle, L., Gouzoulis-Mayfrank, E., Spitzer, M. · 1998 · Pharmacopsychiatry
  43. The discriminative effects of the κ-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects
    Eduardo R. Butelman, Szymon Rus, Thomas Edward Prisinzano, Mary Jeanne Kreek · 2010 · Psychopharmacology
  44. Recreational 3,4- methylenedioxy-N-methylamphetamine (MDMA) or ecstasy and self-focused compassion: preliminary steps in the development of a therapeutic psychopharmacology of contemplative practices
    Kamboj, Sunjeev K, Kilford, Emma J, Minchin, Stephanie, Moss, Abigail, Lawn, Will, Das, Ravi K, Falconer, Caroline J, Gilbert, Paul, Curran, H Valerie, Freeman, Tom P · 2015 · Journal of Psychopharmacology
  45. Considering gender in cannabinoid research: A step towards personalized treatment of marijuana addicts
    Liana Fattore · 2012 · Drug Testing and Analysis
  46. MDMA: a social drug in a social context
    Matthew G. Kirkpatrick, Harriet de Wit · 2014 · Psychopharmacology
  47. Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine
    Isabelle M. Maisonneuve, Stanley D. Glick · 1999 · European Journal of Pharmacology
  48. Hallucinogenic plant use and related indigenous belief systems in the ecuadorian amazon
    Plutarco Naranjo · 1979 · Journal of Ethnopharmacology
  49. Ayahuasca and the Treatment of Drug Addiction
    José Carlos Bouso, Jordi Riba A · 2013 · Springer eBooks
  50. Neurochemical and behavioural interactions between ibogaine and nicotine in the rat
    Maureen E.M. Benwell, P.E. Holtom, Robert J. Moran, David J.K. Balfour · 1996 · British Journal of Pharmacology
  51. Extensive neuroadaptive changes in cortical gene-transcript expressions of the glutamate system in response to repeated intermittent MDMA administration in adolescent rats
    Anna M. S. Kindlundh-Högberg, Anna Blomqvist, Rana Malki, Helgi B. Schiöth · 2008 · BMC Neuroscience
  52. Hallucinogenic Effects of Marijuana as Currently Used
    MARTIN H. KEELER, John A. Ewing, Beatrice A. Rouse · 1971 · American Journal of Psychiatry
  53. Local effects of ibogaine on extracellular levels of dopamine and its metabolites in nucleus accumbens and striatum: interactions withd-amphetamine
    S.D. Glick, Kent L. Rossman, S. Wang, Nan Dong, Richard W. Keller · 1993 · Brain Research
  54. Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague–Dawley rats
    Bryan A. Killinger, M. Melissa Peet, Lisa E. Baker · 2010 · Pharmacology Biochemistry and Behavior
  55. The Varieties of Psychedelic Experience: The Classic Guide to the Effects of LSD on the Human Psyche
    Robert Masters, Jean Houston · 2000 · Medical Entomology and Zoology
  56. Some observations on psilocybin, a new hallucinogen, in volunteer subjects
    Sidney Malitz, Harold Esecover, Bernard Wilkens, Paul H. Hoch · 1960 · Comprehensive Psychiatry
  57. Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial
    John E. Mendelson, Jeremy Coyle, Juan Carlos Rivero López, Matthew J. Baggott, Keith Flower, E. Thomas Everhart, Thomas A. Munro, Gantt P. Galloway, Bruce M. Cohen · 2010 · Psychopharmacology
  58. Ibogaine and the dopaminergic response to nicotine
    I.M. Maisonneuve, S.D. Glick, Gina L Mann, C. R. Deibel · 1997 · Psychopharmacology
  59. Use of Salvia divinorum in a Nationally Representative Sample
    Brian Edward Perron, Brian Kenneth Ahmedani, Michael G. Vaughn, Joseph E. Glass, Arnelyn May Abdon, Li-Tzy T. Wu · 2011 · The American Journal of Drug and Alcohol Abuse
  60. Salvia divinorum use and phenomenology: results from an online survey
    Harry R. Sumnall, Fiona Catherine Measham, Simon D. Brandt, Jon C. Cole · 2010 · Journal of Psychopharmacology
  61. The therapeutic potentials of Ayahuasca in the treatment of depression
    Palhano-Fontes, Fernanda, Alchieri, Joao C., Oliveira, Joao Paulo M., Soares, Bruno Lobao, Hallak, Jaime E. C., Galvao-Coelho, Nicole, de Araujo, Draulio B. · 2014 · The Therapeutic Use of Ayahuasca
  62. Assessment of the Psychotherapeutic Effects of Ritual Ayahuasca Use on Drug Dependency: A Pilot Study
    Fernández, Xavier, dos Santos, Rafael Guimarães, Cutchet, Marta, Fondevila, Sabela, González, Débora, Alcázar, Miguel Ángel, Riba, Jordi, Bouso, José Carlos, María Fábregas, Josep · 2014 · The Therapeutic Use of Ayahuasca
  63. Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats
    Brian Rho, Stanley D. Glick · 1998 · Neuroreport
  64. The subjective experience of acute, experimentally-induced <i>Salvia divinorum</i> inebriation
    Addy, Peter H, Garcia-Romeu, Albert, Metzger, Matthew, Wade, Jenny · 2015 · Journal of Psychopharmacology
  65. Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption
    Kim Wolff, Eva-Maria Tsapakis, Carmine Maria Pariante, Robert W Kerwin, Mary L. Forsling, Katherine Jean Aitchison · 2011 · Journal of Psychopharmacology
  66. A proposed mechanism for the visions of dream sleep
    J. C. Callaway · 1988 · Medical Hypotheses
  67. DPT as an Adjunct in Psychotherapy of Alcoholics
    S Grof, Robert A. Soskin, William A. Richards, A. A. Kurland · 2017 · International Pharmacopsychiatry
  68. Mechanism of Action of Stimulants in Attention-Deficit/Hyperactivity Disorder
    Stephen M. Stahl · 2010 · The Journal of Clinical Psychiatry
  69. Mescaline: the chemistry and pharmacology of its analogs.
    A T Shulgin · 1973 · PubMed
  70. Jesus, Peyote, and the Holy People: Alcohol Abuse and the Ethos of Power in Navajo Healing
    John Garrity · 2000 · Medical Anthropology Quarterly
  71. Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine
    Vishal Panchal, Olga D. Taraschenko, Isabelle M. Maisonneuve, Stanley D. Glick · 2005 · European Journal of Pharmacology
  72. Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans
    Ana Elda Maqueda, Marta Valle, Peter H. Addy, Rosa María Antonijoan, Montserrat Puntes, Jimena Coimbra, María Rosa Ballester, Maite Garrido, M. J. González, Judit Claramunt et al. · 2016 · The International Journal of Neuropsychopharmacology
  73. The Efficacy of LSD in the Treatment of Alcoholism
    Reginald G. Smart, Thomas Storm · 1964 · Quarterly Journal of Studies on Alcohol
  74. Observations on Treatment With Ibogaine
    D Luciano · 1998 · American Journal on Addictions
  75. Life-threatening complications of ibogaine: three case reports.
    Fleur P. Paling, Louise M. Andrews, Gerlof Dirk Valk, H J Blom · 2012 · PubMed
  76. A Historical Review of MDMA
    Steven B. Karch · 2011 · The Open Forensic Science Journal
  77. New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca
    Dennis J. McKenna, Jordi Riba · 2015 · Current topics in behavioral neurosciences
  78. Suggestion in the Treatment of Depression
    Irving Kirsch, Carol B. Low · 2013 · American Journal of Clinical Hypnosis
  79. Observations on the Psychotogenic Effect of N-N Diethyltryptamine, a New Tryptamine Derivative
    Zoltán Böszörményi, Der P, Tibor Zs. Nagy · 1959 · Journal of Mental Science
  80. The Psychedelic Explorer’s Guide: Safe, Therapeutic, and Sacred Journeys
    John Rhead · 2014 · Journal of Psychoactive Drugs
  81. Observations on the Medicinal Properties of the Cannabis Sativa of India
    John Clendinning · 1843 · Journal of the Royal Society of Medicine
  82. Dr. Leary's Concord Prison Experiment: A 34-Year Follow-up Study
    Rick Doblin · 1998 · Journal of Psychoactive Drugs
  83. Mystical and archetypal experiences of terminal patients in DPT-assisted psychotherapy
    William A. Richards · 1978 · Journal of Religion and Health
  84. A new behavior change program using psilocybin.
    Timothy Leary, Ralph Metzner, Presnell Madison, Gunther M. Weil, Schwitzgebel Ralph, Kinne Sara · 1965 · Psychotherapy
  85. Phantastica. Narcotic and Stimulating Drugs. Their Use and Abuse
    n Lewi · 1932 · The Journal of Nervous and Mental Disease
  86. Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans
    Lawrence P. Carter, Chad J. Reissig, Matthew W. Johnson, Margaret A. Klinedinst, Roland R. Griffiths, Miriam Z. Mintzer · 2012 · Drug and Alcohol Dependence
  87. Genetic toxicology of lysergic acid diethylamide (LSD-25)
    Maimon M. Cohen, Yosef Shiloh · 1977 · Mutation Research/Reviews in Genetic Toxicology
  88. The therapeutic potential of harmine and ayahuasca in depression: evidence from exploratory animal and human studies
    Flávia de Lima Osório, Ligia Ribeiro Horta de Macedo, João Paulo Sousa, Joel Porfírio Pinto, João Quevedo, José Alexandre S. Crippa, Jaime E. C. Hallak · 2011
  89. MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblinet al. (2014)
    Andrew C. Parrott · 2014 · Human Psychopharmacology Clinical and Experimental
  90. Chromosomal damage in LDsers
    J. Egozcue · 1968 · JAMA
  91. Psychedelic Drug (DPT)-Assisted Psychotherapy with Alcoholics: A Controlled Study
    John Rhead, Robert A. Soskin, Ibrahim Turek, William A. Richards, Richard Yensen, Albert A. Kurland, Kay Y. Ota · 1977 · Journal of Psychedelic Drugs
  92. The Scheduling of MDMA: A Pharmacist's Perspective
    June E. Riedlinger · 1985 · Journal of Psychoactive Drugs
  93. Is antagonism of α3β4 nicotinic receptors a strategy to reduce morphine dependence?
    Olga D. Taraschenko, Vishal Panchal, Isabelle M. Maisonneuve, Stanley D. Glick · 2005 · European Journal of Pharmacology
  94. The “Vine of the Soul” vs. The Controlled Substances Act: Implications of the Hoasca Case
    Ronald K. Bullis · 2008 · Journal of Psychoactive Drugs
  95. Low Doses of Dipropyltryptamine in Psychotherapy
    Robert A. Soskin · 1973 · Archives of General Psychiatry
  96. Blending Traditions - Using Indigenous Medicinal Knowledge to Treat Drug Addiction 1
    Jacques Mabit, Kartina Amin · 2001
  97. Psychedelic Sacraments
    John Robert Baker · 2005 · Journal of Psychoactive Drugs
  98. Ibogaine related sudden death: A case report
    Stavroula A. Papadodima, Artemisia Dona, Christos I. Evaggelakos, Nikolaos D. Goutas, Sotiris Athanaselis · 2013 · Journal of Forensic and Legal Medicine
  99. Ibogaine-associated ventricular tachyarrhythmias
    Aleš Pleskovič, Vojka Gorjup, Miran Brvar, Gordana Koželj · 2012 · Clinical Toxicology
  100. 2,5-DIMETHOXY-4-METHYLAMPHETAMINE
    Louis A. Faillace, Solomon H. Snyder, Herbert Weingartner · 1970 · The Journal of Nervous and Mental Disease
  101. Acute Stress Symptoms Do Not Worsen in Posttraumatic Stress Disorder and Abuse with a Single Subanesthetic Dose of Ketamine
    Mary C. Zeng, Mark J. Niciu, David A. Luckenbaugh, Dawn Flosnik Ionescu, Daniel C. Mathews, Erica M. Richards, Jose A. Franco-Chaves, Nancy E. Brutsché, Carlos A. Zarate · 2012 · Biological Psychiatry
  102. Dependence studies of new compounds in the rhesus monkey and mouse (1990).
    Mario D. G. Aceto, E R Bowman, Louis S. Harris, E L May · 1990 · PubMed
  103. ibogaine in the treatment of chemical dependence disorders: clinical perspectives
    Howard S. Lotsof · 2016
  104. DPT as an Adjunct in Brief Psychotherapy with Cancer Patients
    Richards, William A., Rhead, John C., Grof, Stanislav, Goodman, Louis E., Di Leo, Francesco, Rush, Lockwood · 1980 · OMEGA - Journal of Death and Dying
  105. MDMA can increase cortisol levels by 800% in dance clubbers
    A. C. Parrott, Jing Zhan Lock, Laura Adnum, Johannes Thome · 2012 · Journal of Psychopharmacology
  106. The treatment and handling of substance dependence with Ayahuasca: Reflections on current and future research
    Harold Yc Tan · 2013 · Journal of Addiction Research & Therapy
  107. Medical risks associated with MDMA use.
    John Aaron Henry, Joseph G. Rella · 2001
  108. Voluntary Drug Self-Administration by Nonhumans; A Review
    Alan D. Poling, John Bryceland · 1979 · Journal of Psychedelic Drugs
  109. Indigenous Supports for Recovery from Alcoholism and Drug Abuse: The Native American Church
    Bob Prue · 2013 · Journal of Ethnic & Cultural Diversity in Social Work
  110. Ibogaine interferes with motivational and somatic effects of naloxone-precipitated withdrawal from acutely administered morphine
    Linda A. Parker, Page Burton, Robert V. McDonald, Joseph A. Kim, Shepard Siegel · 2002 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  111. Hypotheses Regarding Ayahuasca’s Potential Mechanisms of Action in the Treatment of Addiction
    James I. Prickett, Mitchell B. Liester · 2013 · Springer eBooks
  112. The Treatment with Dextromethorphan of Heroin Addicts
    H. Koyuncuoǧlu · 1991 · Springer eBooks
  113. Influence of Age on Salvia Divinorum Use: Results of an Internet Survey
    Pearl P. Nyi, Emily P. Lai, Diana Wing Lee, Shannon A. Biglete, Gilsky I. Torrecer, Ilene B. Anderson · 2010 · Journal of Psychoactive Drugs
  114. Lysergic Acid Diethylamide and Psilocybin Revisited
    Mark A. Geyer · 2015 · Biological Psychiatry
  115. Have Halpern et al. (2004) detected ‘residual neuropsychological effects’ of MDMA? Not likely
    Michael Lyvers, Penelope Anne Hasking · 2004 · Drug and Alcohol Dependence
  116. From LSD to the IRB
    George A. Mashour · 2007 · International Anesthesiology Clinics
  117. Mind‐altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?
    David Nutt · 2014 · EMBO Reports
  118. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results
    Rachelle Smith Doody, Stephen D’Amico, Andrew J. Cutler, Charles S. Davis, Paul Shin, Fred Ledon, Charles Yonan, Joao O. Siffert · 2015 · CNS Spectrums
  119. BIOLOGICAL CHANGES IN MAN FOLLOWING INTRAVENOUS ADMINISTRATION OF MESCALINE
    Pierre Deniker · 1957 · The Journal of Nervous and Mental Disease
  120. PHARMACODYNAMICS OF LSD AND MESCALINE
    Max Rinkel · 1957 · The Journal of Nervous and Mental Disease
  121. Phenethylamines I Have Known and Loved
    Bradley Lenz · 1992 · Journal of Psychoactive Drugs
  122. Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans
    Matthew W. Johnson, Katherine A. MacLean, Michael J Caspers, Thomas Edward Prisinzano, Roland R. Griffiths · 2016 · Journal of Psychopharmacology
  123. The effects of consciousness-expanding drugs on prisoner rehabilitation.
    Timothy Leary · 1969
  124. Targeting the endocannabinoid system to treat haunting traumatic memories
    Irit Akirav · 2013 · Frontiers in Behavioral Neuroscience
  125. Rastafari: From Religion to Social Theory
    Leahcim Tufani Semaj · 1980 · Caribbean Quarterly
  126. Current Status and Future of Cannabis Research
    Ethan B. Russo, Alice Mead, Dustin Sulak · 2015
  127. A call to reprioritise metrics to evaluate illicit drug policy
    Dan Werb, Michel Daniel Kazatchkine, Thomas H Kerr, David Nutt, Steffanie A. Strathdee, Catherine A Hankins, Kanna Hayashi, Julio S. G. Montaner, Don Des Jarlais, Nazlee Maghsoudi et al. · 2016 · The Lancet
  128. LSD: My problem child and insights/outlooks.
    Albert Hofmann, Jonathan Ott, Amanda Feilding · 2013
  129. Constitutional Law: Freedom of Religion: Peyote and the Native American Church
    George de Verges · 1974 · American Indian Law Review
  130. Dependence studies of new compounds in the rhesus monkey and mouse (1991).
    Mario D. G. Aceto, E R Bowman, Louis S. Harris, E L May · 1992 · PubMed
  131. Facilitating transpersonal experiences with dextromethorphan: Potential, cautions, and caveats.
    Peter H. Addy · 2007 · ˜The œJournal of transpersonal psychology